Lipidor Ab
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more
Lipidor Ab (LIPI) - Net Assets
Latest net assets as of December 2024: Skr7.72 Million SEK
Based on the latest financial reports, Lipidor Ab (LIPI) has net assets worth Skr7.72 Million SEK as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr11.58 Million) and total liabilities (Skr3.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr7.72 Million |
| % of Total Assets | 66.68% |
| Annual Growth Rate | 32.08% |
| 5-Year Change | -87.87% |
| 10-Year Change | N/A |
| Growth Volatility | 271.87 |
Lipidor Ab - Net Assets Trend (2016–2024)
This chart illustrates how Lipidor Ab's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lipidor Ab (2016–2024)
The table below shows the annual net assets of Lipidor Ab from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr7.72 Million | +182.69% |
| 2023-12-31 | Skr-9.34 Million | -535.18% |
| 2022-12-31 | Skr2.15 Million | -95.07% |
| 2021-12-31 | Skr43.52 Million | -31.62% |
| 2020-12-31 | Skr63.66 Million | +137.29% |
| 2019-12-31 | Skr26.83 Million | +85.66% |
| 2018-12-31 | Skr14.45 Million | +315.56% |
| 2017-12-31 | Skr3.48 Million | +317.07% |
| 2016-12-31 | Skr833.68K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lipidor Ab's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13087985700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.63 Million | 21.07% |
| Other Components | Skr166.51 Million | 2156.36% |
| Total Equity | Skr7.72 Million | 100.00% |
Lipidor Ab Competitors by Market Cap
The table below lists competitors of Lipidor Ab ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
24SevenOffice Scandinavia AB
ST:247
|
$11.74 Million |
|
Hung Thinh Incons JSC
VN:HTN
|
$11.74 Million |
|
Coal Energy S.A.
WAR:CLE
|
$11.75 Million |
|
Inch Kenneth Kajang Rubber PLC
KLSE:2607
|
$11.75 Million |
|
Workhorse Group Inc
NASDAQ:WKHS
|
$11.74 Million |
|
Soligenix Inc.
NASDAQ:SNGX
|
$11.73 Million |
|
Luo Lih Fen Holding Co Ltd
TW:6666
|
$11.73 Million |
|
K Seng Seng Corporation Bhd
KLSE:5192
|
$11.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lipidor Ab's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -9,339,000 to 7,722,000, a change of 17,061,000.
- Net loss of 13,806,000 reduced equity.
- New share issuances of 32,064,000 increased equity.
- Other factors decreased equity by 1,197,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-13.81 Million | -178.79% |
| Share Issuances | Skr32.06 Million | +415.23% |
| Other Changes | Skr-1.20 Million | -15.5% |
| Total Change | Skr- | % |
Book Value vs Market Value Analysis
This analysis compares Lipidor Ab's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.25x to 12.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr0.01 | Skr0.22 | x |
| 2017-12-31 | Skr0.19 | Skr0.22 | x |
| 2018-12-31 | Skr0.80 | Skr0.22 | x |
| 2019-12-31 | Skr1.33 | Skr0.22 | x |
| 2020-12-31 | Skr2.59 | Skr0.22 | x |
| 2021-12-31 | Skr1.53 | Skr0.22 | x |
| 2022-12-31 | Skr0.07 | Skr0.22 | x |
| 2023-12-31 | Skr-0.13 | Skr0.22 | x |
| 2024-12-31 | Skr0.02 | Skr0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lipidor Ab utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -178.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -98614.29%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.50x
- Recent ROE (-178.79%) is above the historical average (-328.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -584.97% | -1730.45% | 0.11x | 3.02x | Skr-4.96 Million |
| 2017 | -87.49% | -921.82% | 0.07x | 1.32x | Skr-3.39 Million |
| 2018 | -52.85% | -3142.80% | 0.01x | 1.26x | Skr-9.08 Million |
| 2019 | -51.47% | -19177.78% | 0.00x | 1.05x | Skr-16.49 Million |
| 2020 | -25.46% | -2613.55% | 0.01x | 1.03x | Skr-22.57 Million |
| 2021 | -48.70% | -137.84% | 0.28x | 1.26x | Skr-25.55 Million |
| 2022 | -1923.95% | -91751.11% | 0.00x | 7.28x | Skr-41.50 Million |
| 2023 | 0.00% | -14724.36% | 0.03x | 0.00x | Skr-10.55 Million |
| 2024 | -178.79% | -98614.29% | 0.00x | 1.50x | Skr-14.58 Million |
Industry Comparison
This section compares Lipidor Ab's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.